← Browse by Condition
Medical Condition
castrate resistant prostate cancer
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2, Phase 2
NCT06395519 Phase 1, Phase 2
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Enrollment
120 pts
Location
United States
Sponsor
858 Therapeutics, Inc.
NCT05766371 Phase 2
Recruiting
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
Enrollment
48 pts
Location
United States
Sponsor
University of California, San ...